Bioporto ASOCSE:BIOPOR -2.21%69 EBITDA Margin % is -127.40% as of Dec. 2025. GuruFocus rates OCSE:BIOPOR with a GF Score™ of 69/100 and a GF Value™ of kr1.24 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Bioporto AS ranks worse than 85.71% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bioporto AS's EBITDA for the
three
months ended in Dec. 2025 was kr-14.81 Mil. Bioporto AS's Revenue for the
three
months ended in Dec. 2025 was kr11.62 Mil. Therefore, Bioporto AS's EBITDA margin for the quarter that ended in Dec. 2025 was -127.40%.
Bioporto AS (OCSE:BIOPOR) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bioporto AS EBITDA Margin % Related Terms
Bioporto AS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bioporto AS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:BIOPOR vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Bioporto AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bioporto AS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (OCSE:BIOPOR) has a EBITDA Margin % of -127.40% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioporto AS and its competitors. According to the industry distribution chart, Bioporto AS ranks #174 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 85.7%.
Is Bioporto AS's EBITDA Margin % too high?
Bioporto AS's current EBITDA Margin % is -127.40%. Based on the distribution chart, Bioporto AS ranks #174 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Bioporto AS has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #174 out of 203 companies for EBITDA Margin %. This places Bioporto AS in the lower half of its industry. The industry median EBITDA Margin % is 5.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current EBITDA Margin % is -127.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Based on GuruFocus' analysis, Bioporto AS (OCSE:BIOPOR) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.24, compared to a current price of kr1.11 — trading 10.9% below its estimated fair value. The current EBITDA Margin % is -127.40%. Bioporto AS's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bioporto AS (OCSE:BIOPOR), the current EBITDA Margin % is -127.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (OCSE:BIOPOR) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of kr1.11 is trading 10.9% below its estimated GF Value™ of kr1.24.
GuruFocus considers Bioporto AS to be Modestly Undervalued.
Key valuation signals for OCSE:BIOPOR:
EBITDA Margin %: -127.40%
GF Value™: kr1.24 vs. price of kr1.11 (10.9% below fair value)
No single metric tells the full story. See the OCSE:BIOPOR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
69GF Score
Get the complete analysis for OCSE:BIOPOR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:BIOPOR has been successfully added to your 
